News
Iron sucrose injection is an iron replacement product indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease.
Venofer was approved in the U.S. in 2000. It was developed by Vifor Pharma, which is now part of CSL Ltd. American Regent, a unit of Daiichi Sankyo, manufactures and sells it in the U.S. under a ...
Shares of medication company Viatris (NASDAQ:VTRS) jumped 3% in the morning session after it received approval from the U.S.
7h
InvestorsHub on MSNViatris Shares Climb Following FDA Clearance of First Generic Iron Sucrose Injection
Viatris Inc (NASDAQ:VTRS) saw its stock increase by 2.6% after the U.S. Food and Drug Administration approved its Iron ...
Viatris (VTRS) stock gains as the FDA OK its generic Iron Sucrose Injection targeting Venofer marketed by Daiichi Sankyo (DSKYF) (DSNKY) and Vifor. Read more here.
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the U.S. Food and Drug Administration (FDA) has approved Iron Sucrose Injection, USP, an intravenous iron replacement product ...
Investing.com -- Viatris Inc (NASDAQ: VTRS) stock rose 2.6% following the U.S. Food and Drug Administration’s approval of the company’s Iron Sucrose Injection, USP, the first generic version of ...
Q2 2025 Earnings Call Transcript August 7, 2025 Viatris Inc. beats earnings expectations. Reported EPS is $0.62, expectations ...
Iron is a vital mineral that supports bodily functions, but getting it from red meat can also come with some negative health effects. Here are good alternatives.
Chuckwagon cook Kent Rollins reveals the benefits of cooking with cast iron, from its durability and versatility to potential health benefits such as iron enrichment in food.
Oral iron polysaccharide complex is noninferior to intravenous iron sucrose for maintaining iron status over the short-term in patients undergoing maintenance hemodialysis, a trial finds.
After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic versions of Novo Nordisk’s lucrative semaglutide drugs for diabetes and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results